People: Elan Corporation PLC (ELN)

ELN on New York Consolidated

12.36USD
23 May 2013
Price Change (% chg)

$0.32 (+2.66%)
Prev Close
$12.04
Open
$12.15
Day's High
$12.42
Day's Low
$12.15
Volume
30,236,658
Avg. Vol
6,794,239
52-wk High
$14.91
52-wk Low
$9.37

Search Stocks

Summary

Name Age Since Current Position

Robert Ingram

 70 2011 Non-Executive Independent Chairman of the Board

G. Kelly Martin

 54 2008 Chief Executive Officer, Executive Director

Nigel Clerkin

 39 2011 Chief Financial Officer, Executive Vice President

Hans Hasler

 57 2012 Chief Operating Officer

William Daniel

 61 2007 Executive Vice President, Company Secretary

Fabiana Lacerca-Allen

 45 2010 Senior Vice President, Chief Compliance Officer

Guriq Basi

 56 2012 Chief Science & Technology Officer

Grainne McAleese

 33 2011 Principal Accounting Officer, Group Controller

John Given

 43 2013 General Counsel

Menghis Bairu

 49 2012 Chief Medical Officer, Head - Development

Mary Sheahan

 40 2012 Head - Human Resources, IT, Facilities and Portfolio Assessment Management

Gary Kennedy

 55 2005 Non-Executive Independent Director

Patrick Kennedy

 43 2008 Non-Executive Independent Director

Giles Kerr

 53 2007 Non-Executive Independent Director

Kieran McGowan

 69 2006 Lead Independent Non-Executive Director

Kyran McLaughlin

 68 2011 Non-Executive Independent Director

Donal O'Connor

 62 2008 Non-Executive Independent Director

Richard Pilnik

 56 2009 Non-Executive Independent Director

Andrew von Eschenbach

 70 2011 Non-Executive Independent Director

Chris Burns

 Senior Vice President - Investor Relations
» Insider Trading

Biographies

Name Description

Robert Ingram

 Mr. Robert A. Ingram is Non-Executive Independent Chairman of the Board of Elan Corporation PLC. Mr. Ingram was appointed a director of Elan in December 2010. He is currently a general partner of Hatteras Venture Partners, LLC and has served as an advisor to the CEO of GlaxoSmithKline plc since January 2010. Mr. Ingram served as vice chairman pharmaceuticals of GlaxoSmithKline, acting as a special advisor to the corporate executive team from January 2003 until December 2009. He was chief operating officer and president, pharmaceutical operations of GlaxoSmithKline from January 2001 to January 2003. Mr. Ingram was CEO of Glaxo Wellcome plc from 1997 to 2000, and chairman of Glaxo Wellcome Inc. from 1999 to 2000. He is lead director of CREE Inc. and Valeant Pharmaceuticals Inc. and a director of HBM BioVentures AG and Edwards Lifesciences Corporation.

G. Kelly Martin

 Mr. G. Kelly Martin is Chief Executive Officer, Executive Director of Elan Corporation PLC. Mr. Martin was appointed a director of Elan in February 2003 following his appointment as president and CEO. Before joining Elan, Mr. Martin spent more than 20 years at Merrill Lynch & Co., Inc., where he held a broad array of operating responsibilities.

Nigel Clerkin

 Mr. Nigel Clerkin is Chief Financial Officer, Executive Vice President of Elan Corporation PLC. Prior to that, he had served as Senior Vice President, Finance and Group Controller since January 2004. He previously held a number of financial and strategic planning positions since joining the Company in January 1998. Mr. Clerkin is a chartered accountant and a graduate of Queen’s University Belfast.

Hans Hasler

 Mr. Hans Peter Hasler is Chief Operating Officer of Elan Corporation PLC. Mr. Hasler was appointed a non-executive director of Elan in September 2011 and retired in October 2012. He is the Chairman of HBM Healthcare Investments AG and Director of the Board of Acino, Switzerland. Mr. Hasler was principal of HPH Management GmbH. Previously, Mr. Hasler served with Biogen Idec in a number of key executive leadership roles from 2001 to 2009. Prior to his departure from Biogen Idec, Mr. Hasler served as its chief operating officer responsible for all commercial operations, business development, medical affairs and Biogen International. During his tenure, he served as head of global neurology/cardiovascular business and head of International business overseeing the launch of Tysabri in Europe and the management of Avonex. In addition, Mr. Hasler served as chief marketing officer / head of global strategic marketing with Wyeth Pharmaceuticals.

William Daniel

 Mr. William F. Daniel is Executive Vice President & Company Secretary of Elan Corporation PLC. Mr. Daniel was appointed a director of Elan in February 2003 and served till July 2007. He has served as the company secretary since December 2001, having joined Elan in March 1994 as group financial controller. In July 1996, he was appointed group vice president, finance, group controller and principal accounting officer. From 1990 to 1992, Mr. Daniel was financial director of Xtravision, plc. He is a member of the Council of the Institute of Directors in Ireland and is also a Fellow of Chartered Accountants Ireland. Mr. Daniel is a graduate of University College Dublin.

Fabiana Lacerca-Allen

 Ms. Fabiana Lacerca-Allen is Senior Vice President, Chief Compliance Officer of Elan Corporation PLC. Ms. Lacerca-Allen has more than 18 years of compliance and legal experience at Fortune 500 companies and law firms in the United States and in Argentina. She joined Elan from Mylan Laboratories, where she was senior vice president and chief compliance officer and led Mylan’s compliance programs, including the establishment of policies and compliance processes. Prior to her role with Mylan, Lacerca-Allen served as legal compliance director for Bristol-Myers Squibb where she was a member of the executive team for Latin America, Canada and Puerto Rico and led all compliance initiatives in those regions. She has also held positions with Microsoft, Merck, Sharpe & Dohme and AT&T Capital.

Guriq Basi

 Dr. Guriq Basi is Chief Science & Technology Officer of Elan Corporation PLC. Before this Dr. Basi was head of pre-clinical development at Neotope Biosciences, an Elan business unit which specialized in the discovery and development of biologics for the treatment of diseases associated with protein misfolding. Between June 2008 and May 2010, Dr. Basi was vice-president of extramural research at Elan and prior to that was senior director of discovery research and head of molecular biology. Between 1988 and joining Elan in 1992, Dr. Basi was a staff scientist at Protein Design Labs/PDL Biopharma. Dr. Basi undertook postdoctoral research in neurobiology at Stanford University, received his PhD in Biological Chemistry from the University of Illinois at Chicago, and his BA in Biochemistry from The Ohio State University.

Grainne McAleese

 Ms. Grainne McAleese is Principal Accounting Officer, Group Controller of Elan Corporation PLC. Since joining Elan in 2004, Ms. McAleese has worked in a number of roles in the group finance area. Prior to joining Elan, she worked with PricewaterhouseCoopers in New York and KPMG in Dublin. Ms. McAleese is a Certified Public Accountant in the United States, a Fellow of Chartered Accountants Ireland and a graduate of Dublin City University.

John Given

 Mr. John Given is General Counsel of Elan Corporation Plc. Mr. Given was a senior corporate partner at an Irish law firm A&L Goodbody. With more than twenty years of private practice experience, including nine as head of M&A with A&L Goodbody, Mr. Given has advised many Irish and international companies, including many in the life sciences and healthcare sectors. As Elan’s lead external counsel for over a decade, Mr. Given has advised the Company on all of corporate activity for many years and has an understanding of the Company. Mr. Given is a graduate of University College Cork, a solicitor and a member of the Law Society of Ireland.

Menghis Bairu

 Dr. Menghis Bairu, M.D., is Chief Medical Officer and Head - Development of Elan Corporation PLC. Dr. Bairu was appointed executive vice president, chief medical officer and head of global development in 2008. Dr. Bairu served as chief medical officer until September 2010. During his time at Elan Dr. Bairu also served as head of Onclave Therapeutics, an Elan business unit which specialized in developing oncology related assets, and was senior vice president and head of international covering all of Elan’s biopharmaceutical activities outside the United States. Prior to joining Elan, Dr. Bairu worked at Genentech in a number of medical and commercial roles, served on the board of One World Health, a nonprofit drug development company funded by the Bill & Melinda Gates Foundation, and was a director of A-Cube, a privately held pharma start-up. Dr. Bairu also lectures at the University of California San Francisco School of Medicine on global clinical trials’ design, development and conduct.

Mary Sheahan

 Ms. Mary Sheahan is Head - Human Resources, IT, Facilities and Portfolio Assessment Management of Elan Corporation PLC. As part of this role Ms. Sheahan also serves as a director on the board of Janssen Alzheimer Immunotherapy. Since joining Elan in 1997, Ms. Sheahan has held a number of commercial, R&D and corporate finance roles in Ireland and the United States. Most recently she was vice president — finance, tax and treasury from 2007 to 2011. Prior to joining Elan, Ms. Sheahan worked in KPMG in Dublin. Ms. Sheahan holds a Commerce degree and a Masters in Accounting from University College Dublin and is a Fellow of Chartered Accountants Ireland.

Gary Kennedy

 Mr. Gary Kennedy is Non-Executive Independent Director of Elan Corporation PLC. Mr. Kennedy is currently Chairman of Greencore Group plc. Mr. Kennedy is also a director of Friends First Assurance Company, serves as a board member to a number of private companies and was a director of IBRC Limited until February 2013. From May 1997 to December 2005, he was group director, finance and enterprise technology, at Allied Irish Banks, plc (AIB), a member of the main board of AIB, and was also on the board of M&T, AIB’s associate in the United States. Prior to that, Mr. Kennedy was group vice president at Nortel Networks Europe after starting his management career at Deloitte & Touche. He served on the board of the Industrial Development Authority of Ireland for 10 years until he retired in December 2005 and is a Fellow of Chartered Accountants Ireland.

Patrick Kennedy

 Mr. Patrick Kennedy is Non-Executive Independent Director of Elan Corporation PLC. He is currently CEO of Paddy Power plc, an international betting and gaming group, listed on both the London and Irish Stock Exchanges; and is also a director of Bank of Ireland. Mr. Kennedy was previously Chief Financial Officer (CFO) of Greencore Group plc and prior to that worked with McKinsey & Company in both their London and Dublin offices. Mr. Kennedy also previously worked with KPMG’s corporate finance arm, splitting his time between Dublin and the Netherlands. Mr. Kennedy is a graduate of University College Dublin, Trinity College Dublin and a Fellow of Chartered Accountants Ireland.

Giles Kerr

 Mr. Giles F. B. Kerr is no longer Non-Executive Independent Director of Elan Corporation PLC., effective May 30, 2013. He is currently the director of finance with the University of Oxford, England, and a fellow of Keble College. At present Mr. Kerr is a member of the board and the chairman of the audit committee of Victrex plc and BTG plc. He is also a director of Isis Innovation Ltd. and a number of other private companies. Previously, Mr. Kerr was the group finance director and CFO of Amersham plc, and prior to that he was a partner with Arthur Andersen in the United Kingdom. Mr. Kerr is a Fellow of the Institute of Chartered Accountants in England and Wales.

Kieran McGowan

 Mr. Kieran McGowan is Lead Independent Non-Executive Director of Elan Corporation PLC. Mr. McGowan was appointed a director of Elan in December 1998. He is a director Charles Schwab Worldwide Funds plc and was, until May 2012, chairman of CRH plc, as well as sitting on the board of a number of private companies. From 1990 until his retirement in December 1998, Mr. McGowan was chief executive of the Industrial Development Authority of Ireland. He has served as president of the Irish Management Institute and has chaired the Governing Authority at University College Dublin.

Kyran McLaughlin

 Mr. Kyran McLaughlin is Non-Executive Independent Director of Elan Corporation PLC. Mr. McLaughlin was appointed a director of Elan in January 1998 and served as chairman from January 2005 to January 2011. He is deputy chairman at Davy, Ireland’s stockbroker firm. He is also a director of Ryanair Holdings plc and is a director of a number of private companies.

Donal O'Connor

 Mr. Donal O'Connor is Non-Executive Independent Directorof Elan Corporation PLC. Mr. O’Connor was appointed a director of Elan in May 2008 and is also a director of Readymix plc and the administrator of Icarom plc. Prior to joining the Board, Mr. O’Connor was the senior partner of PricewaterhouseCoopers in Ireland from 1995 until 2007. He was also a member of the PricewaterhouseCoopers Global Board and was a former chairman of the Eurofirms Board. Mr. O’Connor is a graduate of University College Dublin and a Fellow of Chartered Accountants Ireland.

Richard Pilnik

 Mr. Richard D. Pilnik is Non-Executive Independent Director of Elan Corporation PLC. Mr. Pilnik was elected a director of Elan in July 2009 and brings industry experience to Elan. Mr. Pilnik served in several leadership positions during his 25-year career at Eli Lilly & Company, most recently as group vice president and chief marketing officer, where he was responsible for commercial strategy, market research and medical marketing. Currently Mr. Pilnik serves as president of Innovex, the commercial group of Quintiles Transnational Corp., which is a global pioneer in pharmaceutical services. Mr. Pilnik holds a B.A. from Duke University and an M.B.A. from the Kellogg School of Management at Northwestern University.

Andrew von Eschenbach

 Dr. Andrew C. von Eschenbach, M.D., is Non-Executive Independent Director of Elan Corporation PLC. He is currently the President of Samaritan Health Initiatives Inc., a health care policy consultancy. He previously served as Commissioner of the FDA from 2005 to 2009. Prior to that he served as the Director of the National Cancer Institute and held a number of leadership roles at the University of Texas’ M.D. Anderson Cancer Center. He was educated at St. Joseph’s University, Philadelphia and received his M.D. from Georgetown University. His current responsibilities include serving on the boards of Histosonics Inc., the Focused Ultrasound Surgery Foundation, Viamet Pharmaceuticals, the National Comprehensive Cancer Centers Network Foundation, BioTime Inc. and its subsidiary OncoCyte Corporation, and Banyan Biomarkers, Inc. He also serves on the advisory boards of Chugai Pharmaceutical International Advisory Council, GE Healthymagination, the Scientific Advisory Board of Arrowhead Research Corporation and is a Senior Fellow at the Milken Institute and director of the FDA Project at the Manhattan Institute.

Chris Burns

Insider Trading

» Full list on Insider Trading
Search Stocks